

Supplementary Figure 1s




Fig. 1s. Pattern of EGFR expression and activation in airway epithelium of healthy and asthmatic subjects. Representative photomicrographs from endobronchial biopsy sections obtained from healthy control and asthmatic subjects. Sections were immunostained for EGFR and phospho-EGFR using the same methods as Fig. 1. Bar = 20 μ m. Immunostaining patterns were similar for asthmatic subjects with and without glucocorticoid treatment.

Supplementary Figure 2s




Fig. 2s. Effect of EKB-569 treatment in vitro and in vivo. **(a)** Human tracheobronchial epithelial cells (hTECs) cultured under air-liquid interface conditions were incubated with or without EGF (100 ng/ml) or IL-13 (100 ng/ml) in the absence or presence of EKB-569 (1 μ M) for 10 min at 37 °C, and corresponding cell lysates were subjected to Western blotting with the indicated antibodies. **(b)** C57BL/6J mice were inoculated with SeV or SeV-UV and then treated with or without EKB-569 on post-inoculation Days 10-21. At post-inoculation Day 21, lung lysates were subjected to Western blotting with the indicated antibodies.